MPH MD - Connect Biopharma Chief Officer
| CNTB Stock | USD 0.98 0.02 2.00% |
Insider
MPH MD is Chief Officer of Connect Biopharma Holdings
| Age | 54 |
| Address | 12265 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 727 1040 |
| Web | https://www.connectbiopharm.com |
Connect Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1213) % which means that it has lost $0.1213 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1792) %, meaning that it created substantial loss on money invested by shareholders. Connect Biopharma's management efficiency ratios could be used to measure how well Connect Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.64. At present, Connect Biopharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 203.4 M, whereas Other Assets are forecasted to decline to 0.00.Similar Executives
| Showing other executives | INSIDER Age | ||
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Susan MS | Eliem Therapeutics | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| David MBA | Seres Therapeutics | 63 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Bradley JD | Lumos Pharma | 45 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| MD BA | Lumos Pharma | 69 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.12 |
Connect Biopharma Leadership Team
Elected by the shareholders, the Connect Biopharma's board of directors comprises two types of representatives: Connect Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Connect. The board's role is to monitor Connect Biopharma's management team and ensure that shareholders' interests are well served. Connect Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Connect Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Chan, Chief Officer | ||
| Raul Collazo, VP Affairs | ||
| Zheng Wei, CoFounder Director | ||
| Barry PharmD, CEO Director | ||
| Lei Sun, VP CMC | ||
| Jiang JD, General Officer | ||
| David Szekeres, President | ||
| Srikanth MD, Senior Development | ||
| David JD, President | ||
| Wubin MBA, President CoFounder | ||
| Malinda Longphre, Head Operations | ||
| MPH MD, Chief Officer |
Connect Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Connect Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.89) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | (55.81 M) | ||||
| Shares Outstanding | 55.25 M | ||||
| Shares Owned By Insiders | 41.16 % | ||||
| Shares Owned By Institutions | 44.42 % | ||||
| Number Of Shares Shorted | 29.4 K | ||||
| Price To Book | 0.49 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.